A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine whether eszopiclone (Eurofarma) is
non-inferior to the reference drug zopiclone (Imovane®, Sanofi-Aventis) in the treatment of
insomnia.